Published in Ned Tijdschr Geneeskd on November 13, 1993
[Tumor markers in the screening, diagnosis and treatment of patients with breast carcinoma]. Ned Tijdschr Geneeskd (1994) 0.75
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med (1988) 4.06
Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet (1994) 3.45
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol (1999) 3.28
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Testicular carcinoma: postmortem diagnosis after a car accident. Lancet (2002) 2.79
Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol (2008) 2.73
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
[The treatment of ductal carcinoma in situ (DCIS) of the breast]. Ned Tijdschr Geneeskd (2003) 2.67
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst (2000) 2.56
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer (2003) 2.40
[Dutch Institute for Healthcare Improvement guideline, "Treatment of breast cancer"]. Ned Tijdschr Geneeskd (2002) 2.39
Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol (2001) 2.28
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol (1997) 2.15
E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer (1997) 2.02
Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology (1995) 1.93
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet (1987) 1.90
High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol (2003) 1.86
Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst (2001) 1.85
The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol (1988) 1.83
Serum insulin-like growth factor-I and breast cancer. Int J Cancer (2000) 1.82
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg (1999) 1.76
Transfusion of red cells is associated with increased incidence of bacterial infection after colorectal surgery: a prospective study. Transfusion (1997) 1.75
Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg (2000) 1.71
Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer (1998) 1.67
[Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology]. Ned Tijdschr Geneeskd (2000) 1.59
Histological determinants for different types of local recurrence after breast-conserving therapy of invasive breast cancer. Dutch Study Group on local Recurrence after Breast Conservation (BORST) Eur J Cancer (1999) 1.55
Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res (1992) 1.53
Recurrent esophageal fibrovascular polyps: case history and review of the literature. Dig Dis Sci (2002) 1.51
Cancer incidence in relatives of patients with testicular cancer in the eastern part of The Netherlands. Urology (2001) 1.51
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer (2003) 1.50
Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer (2000) 1.50
Clear cell sarcoma (malignant melanoma) of soft parts: A clinicopathologic study of 30 cases. Cancer (1999) 1.46
Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45
Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. Eur J Surg Oncol (2001) 1.44
[Diagnostics in clinically occult, radiologically suspect breast lesions more often surgery than needle diagnostics with image monitoring]. Ned Tijdschr Geneeskd (2001) 1.43
Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res (1990) 1.43
Small-bowel perforation complicating the open treatment of generalized peritonitis. Arch Surg (1989) 1.42
Steroid receptor heterogeneity in relation to DNA index in breast cancer: a multiparameter flow cytometric approach on paraffin-embedded tumor samples. Breast J (2001) 1.42
[Identification of the sentinel node in patients with breast carcinoma]. Ned Tijdschr Geneeskd (1996) 1.42
[Detailed pathological examination of the sentinel lymph nodes in order to detect micrometastases: no clinical relevance in patients with breast cancer]. Ned Tijdschr Geneeskd (2004) 1.40
Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res (1997) 1.35
"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer (1991) 1.35
Lymphoepithelioma-like carcinoma of the breast: lack of evidence of Epstein-Barr virus infection. Histopathology (2001) 1.32
Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol (1993) 1.32
Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer (2003) 1.31
Expression of oestrogen receptor and loss of E-cadherin are diagnostic for gastric metastasis of breast carcinoma. Histopathology (2005) 1.27
CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer (2005) 1.26
Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch (1999) 1.24
Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res (1999) 1.24
Acinic cell carcinoma of the breast: an immunohistochemical and ultrastructural study. Virchows Arch (2000) 1.24
Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat (1991) 1.23
Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer (2001) 1.22
Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psychooncology (2000) 1.22
Immune complex detection by immunofluorescence on polymorphonuclear leucocytes. Clin Exp Immunol (1977) 1.21
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology (2007) 1.21
In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology (2001) 1.21
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. Cancer Res (1994) 1.21
No common denominator for breast cancer lymph node metastasis. Br J Cancer (2005) 1.20
Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. Am J Epidemiol (1997) 1.20
Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol (2004) 1.19
Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. Virchows Arch (2004) 1.19
Frozen section investigation of the sentinel node in malignant melanoma and breast cancer. Ann Surg Oncol (2001) 1.19
Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions. Br J Cancer (2004) 1.18
Epidemiology of Crohn's disease in Regio Leiden, The Netherlands. A population study from 1979 to 1983. Gastroenterology (1987) 1.17
Immunohistochemical categorisation of ductal carcinoma in situ of the breast. Br J Cancer (2007) 1.17
Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type. Br J Cancer (1999) 1.17
Marital satisfaction in patients with cancer: does support from intimate partners benefit those who need it the most? Health Psychol (2000) 1.16
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol (1996) 1.16
Breast-conserving therapy for Paget disease of the nipple: a prospective European Organization for Research and Treatment of Cancer study of 61 patients. Cancer (2001) 1.16
Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer (1987) 1.14
Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer (1996) 1.13
Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol (1997) 1.13
In-situ breast cancer: the EORTC consensus meeting. Lancet (1989) 1.13
MAM-6 antigen, a new serum marker for breast cancer monitoring. Cancer Res (1986) 1.11
Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer (2005) 1.10
Expression and release of CD27 in human B-cell malignancies. Blood (1993) 1.10
Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. J Pathol (2009) 1.09
Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description. Virchows Arch (2002) 1.09
Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer (1988) 1.08
Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast. J Pathol (1999) 1.08
Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs (2001) 1.08
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol (2006) 1.08
Alveolar soft part sarcoma. a report of 15 cases. Eur J Cancer (2002) 1.08
The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat (2010) 1.07
Primary axillary radiotherapy as axillary treatment in breast-conserving therapy for patients with breast carcinoma and clinically negative axillary lymph nodes. Cancer (2000) 1.07
Quality of life as an outcome measure in surgical oncology. Br J Surg (2001) 1.07
Human breast cancer: survival from first metastasis. Breast Cancer Study Group. Breast Cancer Res Treat (1992) 1.07
Incidence and clinical course of de-novo malignancies in renal allograft recipients. Eur J Surg Oncol (2001) 1.07
The effect of antineoplastic agents on the healing of small intestinal anastomoses in the rat. Cancer (1986) 1.05
Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA. Oncogene (1988) 1.05
Body fat mass, body fat distribution, and plasma hormones in early puberty in females. J Clin Endocrinol Metab (1990) 1.04
Malignant neoplasms infiltrating pseudoangiomatous' stromal hyperplasia of the breast: an unrecognized pathway of tumour spread. Histopathology (2002) 1.04
Consistency achieved by 23 European pathologists in categorizing ductal carcinoma in situ of the breast using five classifications. European Commission Working Group on Breast Screening Pathology. Hum Pathol (1998) 1.04
Genetic polymorphisms in UDP-glucuronosyltransferases and glutathione S-transferases and colorectal cancer risk. Carcinogenesis (2004) 1.04